HTR1A and schizophrenia: Cariprazine, a partial agonist at dopamine D2/D3 receptors with higher D3 affinity, also targets serotonin 5-HT1A/5-HT2A receptors, but research on its use in OCD is limited: a case report described rapid OCD symptom remission in a schizophrenia patient after adding cariprazine to long-acting paliperidone (De Berardis et al., 2020), while a recent small retrospective study highlighted its potential effectiveness and safety as augmentation strategy in treatment-resistant OCD (Martiadis et al., 2024a).